- Home
- DSGX vs LEGN Comparison
DSGX vs LEGN Comparison
Compare DSGX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGX
- LEGN
- Stock Information
- Founded
- DSGX 1981
- LEGN 2014
- Country
- DSGX Canada
- LEGN United States
- Employees
- DSGX N/A
- LEGN N/A
- Industry
- DSGX Computer Software: Prepackaged Software
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- DSGX Technology
- LEGN Health Care
- Exchange
- DSGX Nasdaq
- LEGN Nasdaq
- Market Cap
- DSGX 8.8B
- LEGN 5.4B
- IPO Year
- DSGX 1999
- LEGN 2020
- Fundamental
- Price
- DSGX $101.87
- LEGN $38.96
- Analyst Decision
- DSGX Buy
- LEGN Strong Buy
- Analyst Count
- DSGX 7
- LEGN 12
- Target Price
- DSGX $125.14
- LEGN $73.91
- AVG Volume (30 Days)
- DSGX 453.2K
- LEGN 1.6M
- Earning Date
- DSGX 09-03-2025
- LEGN 08-08-2025
- Dividend Yield
- DSGX N/A
- LEGN N/A
- EPS Growth
- DSGX 17.84
- LEGN N/A
- EPS
- DSGX 1.65
- LEGN N/A
- Revenue
- DSGX $668,391,000.00
- LEGN $728,303,000.00
- Revenue This Year
- DSGX $11.87
- LEGN $65.49
- Revenue Next Year
- DSGX $13.36
- LEGN $53.76
- P/E Ratio
- DSGX $61.29
- LEGN N/A
- Revenue Growth
- DSGX 13.74
- LEGN 112.46
- 52 Week Low
- DSGX $90.61
- LEGN $27.34
- 52 Week High
- DSGX $124.31
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- DSGX 46.22
- LEGN 66.26
- Support Level
- DSGX $101.06
- LEGN $34.64
- Resistance Level
- DSGX $104.41
- LEGN $39.88
- Average True Range (ATR)
- DSGX 2.38
- LEGN 1.46
- MACD
- DSGX 0.49
- LEGN 0.37
- Stochastic Oscillator
- DSGX 54.96
- LEGN 87.67
About DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.